NGM · Financial Statements

Climb Bio, Inc. (CLYM) Financial Statements

$10.19 NGM: CLYM Market Cap $585.28M

Climb Bio, Inc. most recently reported annual revenue of $0, a net loss of $60.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Climb Bio, Inc.: net profit was positive in 0 of 7 reported years; the most recent year shows a net loss of $60.0M.

Income Statement — 7 Years (USD millions)

Metric2019202020212022202320242025
Revenue$0$0$0$0$0$0$0
Operating Expenses$7.0M$21.0M$36.0M$45.0M$40.0M$82.0M$68.0M
Operating Profit$-7.0M$-21.0M$-36.0M$-45.0M$-40.0M$-82.0M$-68.0M
Operating Margin0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Other Income$1.0M$0$-12.0M$0$5.0M$8.0M$8.0M
Interest$0$0$0$0$0$0$0
Depreciation$0$0$0$0$0$0$0
Profit Before Tax$-7.0M$-21.0M$-47.0M$-45.0M$-35.0M$-74.0M$-60.0M
Tax$0$0$0$0$0$0$0
Net Profit$-7.0M$-21.0M$-47.0M$-45.0M$-35.0M$-74.0M$-60.0M
EPS$-0.56$-1.97$-4.24$-1.72$-1.30$-1.53$-0.88
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$0$0$0$0$0$0$0$0$0$0$0$0
Operating Expenses$5.0M$5.0M$3.0M$56.0M$12.0M$11.0M$23.0M$11.0M$15.0M$19.0M$15.0M$15.0M
Operating Profit$-5.0M$-5.0M$-3.0M$-56.0M$-12.0M$-11.0M$-23.0M$-11.0M$-15.0M$-19.0M$-15.0M$-15.0M
Operating Margin0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$-4.0M$-4.0M$-2.0M$-55.0M$-9.0M$-8.0M$-21.0M$-9.0M$-13.0M$-18.0M$-14.0M$-13.0M
Tax$0$0$0$0$0$0$0$0$0$0$0$0
Net Profit$-4.0M$-4.0M$-2.0M$-55.0M$-9.0M$-8.0M$-21.0M$-9.0M$-13.0M$-18.0M$-14.0M$-13.0M
EPS$-0.15$-0.13$-0.06$-1.81$-0.13$-0.13$-0.31$-0.13$-0.19$-0.26$-0.20$-0.18

Over the 7 years reported for Climb Bio, Inc., cash stood at $36.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 15.14 times.

Balance Sheet — 7 Years (USD millions)

Metric2019202020212022202320242025
Total Assets$21.0M$25.0M$173.0M$135.0M$110.0M$217.0M$168.0M
Current Assets$21.0M$22.0M$148.0M$134.0M$110.0M$155.0M$106.0M
Cash$21.0M$20.0M$47.0M$44.0M$93.0M$87.0M$36.0M
Inventory$0$0$0$0$0$0$0
Receivables$0$0$7.0M$6.0M$2.0M$1.0M$0
Fixed Assets$0$0$0$0$0$0$1.0M
Capital Work in Progress$0$0$0$0$0$0$0
Investments$0$0$114.0M$80.0M$14.0M$125.0M$125.0M
Other Assets$0$0$0$0$0$0$0
Total Liabilities$1.0M$3.0M$6.0M$6.0M$3.0M$5.0M$7.0M
Current Liabilities$1.0M$3.0M$6.0M$6.0M$3.0M$5.0M$7.0M
Borrowings$0$0$0$0$0$1.0M$1.0M
Other Liabilities$1.0M$3.0M$6.0M$6.0M$3.0M$5.0M$7.0M
Equity$0$0$0$0$0$0$0
Reserves$21.0M$22.0M$167.0M$129.0M$108.0M$212.0M$160.0M

For Climb Bio, Inc., operating cash flow was positive in 0 of 7 reported years; free cash flow in the latest year was negative at $55.0M; free cash flow was positive in 0 of 7 years.

Cash Flow Statement — 7 Years (USD millions)

Metric2019202020212022202320242025
Operating Cash Flow$-5.0M$-14.0M$-36.0M$-37.0M$-21.0M$-16.0M$-54.0M
Investing Cash Flow$0$8.0M$-115.0M$34.0M$69.0M$-121.0M$3.0M
Financing Cash Flow$0$0$0$0$0$11.0M$0
Net Cash Flow$21.0M$-1.0M$26.0M$-3.0M$50.0M$-6.0M$-52.0M
Free Cash Flow$-5.0M$-14.0M$-36.0M$-37.0M$-21.0M$-16.0M$-55.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.65
EV / EBITDA-9.83
FCF Yield-8.47%
Quick Ratio31.45
Interest Coverage—
Return 1Y762.16%
Return 3Y340.00%
Return 5Y—

Climb Bio, Inc. (CLYM) financials — frequently asked questions

What is Climb Bio, Inc.'s annual revenue?

Climb Bio, Inc. (CLYM) reported annual revenue of $0 in its most recent fiscal year.

What is Climb Bio, Inc.'s net profit?

Climb Bio, Inc. (CLYM) reported a net loss of $60.0M in its most recent fiscal year.

What is CLYM EV/EBITDA?

Climb Bio, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -9.83. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
CLYM Overview CLYM Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.